Real World Canadian Case Series: Use of Tildrakizumab for Moderate to Severe Psoriasis Peptides Lack Reliable Safety Information, Watchdog Warns Inflammatory memory in psoriasis: From remission to recurrence Journal of Allergy and Clinical Immunology Many treatment guidelines for psoriasis rely heavily on body surface area (BSA) involvement to determine disease severity and eligibility for systemic therapies like biologics. Traditionally, patients with less than 10% BSA involvementespecially